CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug 1, 2018--Akebia Therapeutics, Inc. (NASDAQ:AKBA), a biopharmaceutical company focused on delivering innovative therapies to patients with kidney disease through the biology of hypoxia-inducible factor (HIF), today announced it will host a second quarter 2018 investor update conference call and webcast at 4:30 p.m. on Wednesday, August 8, 2018.

Individuals interested in participating in the call should dial (877) 458-0977 (U.S. and Canada) or (484) 653-6724 (international) using conference ID number 1398303. To access the webcast, visit the Investors section of Akebia’s website at www.akebia.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.

Beginning the morning of August 9, 2018, the call will be available for replay via telephone and the archived webcast will be available on Akebia’s website. To listen to the telephone replay, dial (855) 859-2056 (U.S. and Canada) or (404) 537-3406 (international) using conference ID number 1398303. The telephone replay will be available for six days following the call.

About Akebia Therapeutics

Akebia Therapeutics, Inc. is a biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on delivering innovative therapies to patients with kidney disease through hypoxia-inducible factor biology. For more information, please visit our website at www.akebia.com, which does not form a part of this release.

View source version on businesswire.com:https://www.businesswire.com/news/home/20180801005888/en/

CONTACT: Akebia Therapeutics

John Garabo, 617-844-6130

Director, Corporate Communications

jgarabo@akebia.com

KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL

SOURCE: Akebia Therapeutics, Inc.

Copyright Business Wire 2018.

PUB: 08/01/2018 04:05 PM/DISC: 08/01/2018 04:06 PM

http://www.businesswire.com/news/home/20180801005888/en